Clebopride

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Clebopride
Accession Number
DB13511
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • Cleboprida
External IDs
LAS 9273
Categories
UNII
I0A84520Y9
CAS number
55905-53-8
Weight
Average: 373.88
Monoisotopic: 373.1557047
Chemical Formula
C20H24ClN3O2
InChI Key
BVPWJMCABCPUQY-UHFFFAOYSA-N
InChI
InChI=1S/C20H24ClN3O2/c1-26-19-12-18(22)17(21)11-16(19)20(25)23-15-7-9-24(10-8-15)13-14-5-3-2-4-6-14/h2-6,11-12,15H,7-10,13,22H2,1H3,(H,23,25)
IUPAC Name
4-amino-N-(1-benzylpiperidin-4-yl)-5-chloro-2-methoxybenzamide
SMILES
COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC2=CC=CC=C2)CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Clebopride.
BenzatropineThe risk or severity of adverse effects can be increased when Clebopride is combined with Benzatropine.
BrexpiprazoleThe therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Clebopride.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Clebopride.
CabergolineThe therapeutic efficacy of Cabergoline can be decreased when used in combination with Clebopride.
DeutetrabenazineThe risk or severity of adverse effects can be increased when Clebopride is combined with Deutetrabenazine.
DexpramipexoleThe therapeutic efficacy of Dexpramipexole can be decreased when used in combination with Clebopride.
DihydrexidineThe therapeutic efficacy of Dihydrexidine can be decreased when used in combination with Clebopride.
DihydroergocornineThe therapeutic efficacy of Dihydroergocornine can be decreased when used in combination with Clebopride.
DihydroergocryptineThe therapeutic efficacy of Dihydroergocryptine can be decreased when used in combination with Clebopride.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
2678
BindingDB
50132693
ChEBI
92309
ChEMBL
CHEMBL325109
Wikipedia
Clebopride
ATC Codes
A03FA06 — Clebopride

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0198 mg/mLALOGPS
logP2.69ALOGPS
logP2.42ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)14.61ChemAxon
pKa (Strongest Basic)8.52ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.59 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity106.07 m3·mol-1ChemAxon
Polarizability39.81 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Benzylpiperidines
Direct Parent
N-benzylpiperidines
Alternative Parents
Aminophenyl ethers / Methoxyanilines / Phenylmethylamines / Phenoxy compounds / Anisoles / Methoxybenzenes / Benzylamines / Alkyl aryl ethers / Aralkylamines / Chlorobenzenes
show 9 more
Substituents
N-benzylpiperidine / Methoxyaniline / Aminophenyl ether / Anisole / Benzylamine / Phenol ether / Phenylmethylamine / Aniline or substituted anilines / Phenoxy compound / Methoxybenzene
show 27 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:43 / Updated on June 04, 2019 07:54